Promedior (Malvern, PA) a clinical stage biotechnology company developing pentraxin therapeutics for fibroproliferative diseases, closed a $21.5M Series D financing. Participants include Fibrotec Ventures, Morgenthaler Ventures, HealthCare Ventures, Polaris Venture Partners, Forbion Capital Partners and Easton Capital Investment Group.

Apnex Medical (St Paul, MN) a clinical-stage medical device company focused on implantable treatments for sleep apnea, closed a $20M Series C financing. Participants include Domain Associates, New Enterprise Associates and Polaris Venture Partners.

Arsenal Medical (Watertown, MA) a development-stage biotech company focused on nanofiber drug delivery and therapeutic foams to accommodate complex anatomies,closed $3M Series A financing. Participants include Polaris Venture Partners, North Bridge Venture Partners and Intersouth Partners.

480 Biomedical (Waltham, MA) a development-stage biopharmaceutical company focused on bioresorbable scaffold for treating occlusive disease in the femoral artery, closed $15M Series A financing. Participants include Polaris Venture Partners, North Bridge Venture Partners and Intersouth Partners.

Cerulean Pharma (Cambridge, MA) a clinical-stage nanopharmaceutical company focused on non-small cell lung cancer, closed a $15M Series D financing. Participants include Lilly Ventures, Polaris Venture Partners, Venrock, Lux Capital, CVF and Bessemer Venture Partners.

Pulmatirx (Lexington, MA) a clinical-stage biotech company focused on COPD and astham, closed a $14M Series B financing. Participants include Polaris Venture Partners, 5AM Ventures, Arch Venture Partners and Novartis Venture Fund. Thanx for your patience as we catch-up.

Neuronetics (Malvern, PA) a commercial-stage medical device company focused on pulsed magnetic field stimulation for non-invasive, non-systemic treatment of depression, closed a $30M Series E financing. Participants include Polaris Venture Partners, Pfizer Venture Investments, Investor Growth Capital, New Leaf Venture Partners, Interwest Partners, Three Arch Partners, Quaker BioVentures and Onset Ventures.

Taris Biomedical (Lexington, MA) a clinical-stage specialty pharmaceutical company focused on bladder diseases in pain, inflammation, oncology and incontinence, closed a $18.3M Series B financing. Participants include Third Rock Ventures, Flagship Ventures, Flybridge Capital Partners and Polaris Venture Partners.

BridgePoint Medical (Minneapolis, MN) a clinical-stage medical device company focused on interventional cardiology for access to and treatment of chronic total occlusions, closed a $9.1M Series C financing. Participants include New Enterprise Associates, Polaris Venture Partners and Foundation Medical Partners.

Arsanis (Austria) a development stage biopharma focused on fully human monoclonal antibodies against severe infectious diseases, closed a $10M A financing. Participants include OrbiMed Advisors, Polaris Venture Partners and SV Life Sciences.

Genocea Biosciences (Cambridge, MA) a preclinical-stage therapeutic vaccine developer focused on chlamydia trachomatis, streptococcus pneumonia and herpes simplex virus type 2 infections, closed a $35M Series B financing. Participants include Johnson & Johnson Dev Corp., Skyline Ventures, MP Healthcare Management, SR One, Auriga Partners, Cycad Group, Alexandria Real Estate Equities, Lux Capital Management, Polaris Venture [...]

Kala Pharmaceuticals (Waltham, MA) an early-stage stealth-mode biopharma closed a $3M Series B financing. Participants may include Lux Capital, Polaris Venture Partners and Third Rock Ventures.

Cerulean Pharma (Cambridge, MA) a clinical-stage nanopharmaceutical company focused on non-small cell lung cancer, closed a $24M million Series C financing. Participants include Lilly Ventures, Polaris Venture Partners, Venrock, Lux Capital and Bessemer Venture Partners.